Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Davoren

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Medicinal Chemistry|November 16, 2018
Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced DesensitizationJennifer E Davoren, Deane Nason, Jotham Coe, et al.
Frontiers in Pharmacology|August 1, 2020
Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic ActivationRouba Kozak, Tamás Kiss, Keith Dlugolenski, et al.
Journal of Medicinal Chemistry|June 10, 2017
Design and Synthesis of γ- and δ-Lactam M<sub>1</sub> Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M<sub>1</sub>-Selective PAM with Weak Agonist ActivityJennifer E Davoren, Michelle Garnsey, Betty Pettersen, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2015
Design and optimization of selective azaindole amide M1 positive allosteric modulatorsJennifer E Davoren, Steven V O'Neil, Dennis P Anderson, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2015
Discovery of a novel Kv7 channel opener as a treatment for epilepsyJennifer E Davoren, Michelle M Claffey, Sheri L Snow, et al.
Nature Communications|May 16, 2025
Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca<sup>2+</sup> dependent allosteric binding siteLeslie A Dakin, Li Xing, Justin Hall, et al.
Journal of Medicinal Chemistry|June 9, 2016
Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side EffectsJennifer E Davoren, Che-Wah Lee, Michelle Garnsey, et al.
Nature Communications|March 10, 2026
Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitisJennifer L Duffen, Kimberly K Crouse, Lin Ji, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Medicinal Chemistry|November 16, 2018
Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced DesensitizationJennifer E Davoren, Deane Nason, Jotham Coe, et al.
Frontiers in Pharmacology|August 1, 2020
Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic ActivationRouba Kozak, Tamás Kiss, Keith Dlugolenski, et al.
Journal of Medicinal Chemistry|June 10, 2017
Design and Synthesis of γ- and δ-Lactam M<sub>1</sub> Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M<sub>1</sub>-Selective PAM with Weak Agonist ActivityJennifer E Davoren, Michelle Garnsey, Betty Pettersen, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2015
Design and optimization of selective azaindole amide M1 positive allosteric modulatorsJennifer E Davoren, Steven V O'Neil, Dennis P Anderson, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2015
Discovery of a novel Kv7 channel opener as a treatment for epilepsyJennifer E Davoren, Michelle M Claffey, Sheri L Snow, et al.
Nature Communications|May 16, 2025
Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca<sup>2+</sup> dependent allosteric binding siteLeslie A Dakin, Li Xing, Justin Hall, et al.
Journal of Medicinal Chemistry|June 9, 2016
Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side EffectsJennifer E Davoren, Che-Wah Lee, Michelle Garnsey, et al.
Nature Communications|March 10, 2026
Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitisJennifer L Duffen, Kimberly K Crouse, Lin Ji, et al.
Pageof 2